Profarma 2Q26 adjusted EBITDA rises 25.4% to R$ 126.6 million; revenue climbs 31.4% to R$ 4.1 billion

• Profarma posted 2Q26 gross revenue of R$ 4.1 billion, up 31.4% year over year; adjusted EBITDA rose 25.4% to R$ 126.6 million.
• Adjusted EBITDA margin narrowed to 3.5% from 3.7%, reflecting the inclusion of newly acquired 4BIO, which ran a 2.2% margin.
• Adjusted net income climbed 23.7% to R$ 31.7 million; operating cash generation over the last 12 months rose 76.5% to R$ 378.3 million.
• Net leverage ended the quarter at 2.9x net debt/EBITDA, including R$ 511 million in acquisition obligations; it would have been 2.2x excluding 4BIO.
• Management highlighted the May 4 acquisition of 4BIO and said logistics synergies should be captured progressively from July, supporting second-half margin gains.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profarma Distribuidora de Produtos Farmacêuticos SA published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.